|
Patent landscape, scope, and claims: |
United States Patent 7,977,488 scope, claims, and competitive patent landscape for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
US Patent 7,977,488 is a US small-molecule composition claim centered on 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (and salts). The enforceable scope is driven by (i) the specificity of the chemical structure recited in claim 1, (ii) salt coverage, and (iii) whether dependent claims (not provided) add additional structural or method limits (e.g., polymorphs, formulations, stereochemistry, specific salt identities, or therapeutic use).
Claim 1, as provided, is a “compound plus salt” coverage hook with narrow chemical identity but broad salt capture. That structure-level specificity typically creates high invalidity risk for challengers only if they can design around by changing the scaffold or sulfonamide/pyridyl substitution pattern. It also creates high infringement risk for any product that uses the exact same active compound (or a covered salt form).
What exactly does US patent 7,977,488 claim, and how broad is claim 1’s compound coverage?
Claim 1 (provided):
“1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof.”
What is protected in claim 1
Entity covered: the exact named chemical entity plus salts.
Breaking the claim’s language into enforceable anchors:
- Core ring system: 1H-pyrrole substituted at N-1 and at C-3 (as written).
- N-substitution at 1-position: pyridin-3-ylsulfonyl group attached to the pyrrole nitrogen (a sulfonamide/sulfonyl linkage pattern as stated).
- C-5 substitution: 2-fluorophenyl at the 5-position of the pyrrole.
- C-3 substituent: a methanamine sidechain, N-methyl substituted (N-methylmethanamine).
- Salt coverage: “or a salt thereof” extends protection to pharmaceutically acceptable salts and potentially to non-acceptable salts depending on how the specification defines “salt.”
What claim 1 does not cover (by default)
Because claim 1 is a single, tightly recited compound definition, it does not automatically cover:
- other salts where the claim construction limits “salt” to those exemplified or defined in the specification (this depends on claim interpretation and how the specification treats salts);
- polymorphs, solvates, hydrates, or amorphous forms (unless dependent claims capture them, or the specification supports product-by-process or solid-state embodiments in the claims);
- formulations (tablet, capsule, spray-dried dispersion, etc.) unless dependent claims include composition/formulation language;
- methods of treatment (unless dependent claims include “use” or “method” limitations).
Practical scope statement
For infringement analysis, the central question is whether an accused product’s active ingredient is the same chemical identity or a salt of that identity. If the scaffold is modified (ring positions, sulfonyl attachment pattern, pyridinyl position, fluorine position, sidechain amine substitution), claim 1 typically does not read on the altered structures.
How do courts typically construe “or a salt thereof” for US compound claims like 7,977,488?
Salt phrase mechanics are often outcome-determinative. In US litigation, “salt” coverage usually turns on claim construction and whether the specification supports the scope of “salt.”
Key infringement vectors created by “salt thereof”
- If a drug candidate uses the claimed base as freebase and forms a salt in manufacturing or final dosage, it is within the “salt” literal scope if the salt is within the claim construction.
- If a competitor uses a different counterion that is still recognized as a salt of the same base, the compound may still infringe claim 1, subject to how “salt” is construed.
Typical design-around approach
Competitors often avoid claim 1 either by:
- changing the chemical identity of the base (stronger design-around), or
- using a form that is argued not to be “a salt” within the intrinsic evidence of the patent (weaker design-around, more fact-dependent).
What other claims likely exist beyond claim 1, and how do they change enforcement risk?
Only claim 1 is provided. US patents covering a single compound frequently include a set of dependent claims that narrow into:
- specific salts (e.g., hydrochloride, sulfate, fumarate),
- specific stereochemistry (if the scaffold allows),
- specific crystalline forms (polymorphs),
- pharmaceutical compositions comprising the compound,
- intermediates and/or manufacturing steps (for chemical patents with broad synthetic coverage).
Without the full claims text, the enforceable landscape beyond claim 1 cannot be fully enumerated. What can be asserted from the single provided claim is:
- The minimum enforceable subject matter includes the compound identity and salts.
- Any additional dependent coverage would likely expand into formulation, solid-state, or use claims, increasing total infringement entry points.
What patents protect the same compound or close analogs around US 7,977,488?
A compound of this specificity typically sits inside a broader patent family that covers:
- synthesis intermediates,
- process claims,
- salt selection and preparation,
- formulation claims,
- polymorph/solid-state claims,
- and sometimes method-of-use claims in a therapeutic area.
However, a complete US landscape requires the full patent publication details (application number, assignee, earliest priority, and family members) and a patent database record for cross-referencing. Those data are not included in the prompt.
Given only claim 1 text, the defensible scope statement is limited to:
- US 7,977,488 claim 1 protects one named compound plus salts.
- Related protection may exist, but cannot be enumerated reliably without family and citation data.
How long does US 7,977,488 last, and when does exclusivity end for claim 1’s compound?
Patent term analysis requires:
- filing date,
- earliest effective filing date,
- and any PTA (patent term adjustment) information,
- plus whether there are terminal disclaimers.
No filing or priority dates were provided. Therefore, the exclusivity timeline for US 7,977,488 cannot be calculated from the prompt content alone.
What is the “Orange Book” status likely for a compound covered by US 7,977,488?
Orange Book status depends on:
- whether the compound is the active ingredient of an FDA-approved drug,
- whether US 7,977,488 is listed as covering a drug product (active moiety and patent listing),
- whether the listed patents cover drug substance, drug product, or method of use.
No FDA NDA/ANDA and no Orange Book listing data were provided. The claim text alone does not identify a drug product, label, sponsor, or approved indication.
Which generic entry risks exist for products using 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or its salts?
For claim 1, generic entry risk is high if the generic:
- uses the same active compound (or same salt form within claim construction), and
- seeks FDA approval for a product that relies on the branded reference listed patents that include US 7,977,488.
The litigation trigger is usually a Paragraph IV notice tied to the Orange Book listing. Without Orange Book listing linkage, the Paragraph IV pathway and timing cannot be validated from the prompt.
How strong is the patent estate for US 7,977,488 given only claim 1?
Strength signals for claim 1:
- High identity specificity reduces the risk of inadvertent overbreadth.
- That specificity can still be a strength because exact structural infringement is straightforward to analyze when the accused compound is known.
Strength limits for claim 1:
- If the market uses different analogs or different salt forms outside claim construction, enforcement may be narrow.
- If claim set includes only compound coverage and not formulations or uses, product-level infringement may depend strictly on active ingredient identity.
A strength assessment for the broader estate requires full claim set, family members, priority dates, and prosecution history.
What product forms would infringe claim 1: API vs finished dosage?
Claim 1 covers the compound “or a salt thereof.” Typically:
- Infringement can occur at the API level if the accused party manufactures, sells, or imports the covered compound or salt.
- Finished dosage forms also infringe if they contain the covered compound or salt as the active ingredient, regardless of formulation excipients, unless separate claims are required for product-form infringement.
If additional dependent claims require a specific formulation or particle size (not provided), those would further constrain scope.
How does US 7,977,488 compare to adjacent patent claims that typically matter in compound litigation?
For compound-centric patents, the usual competitive difference is between:
- compound claims (like this one),
- salt-only claims (often narrower but sometimes easier to design around),
- process claims (can be circumvented by alternative synthesis routes),
- formulation claims (can be circumvented by changing dosage form),
- method-of-use claims (harder to design around if same clinical regimen is used).
From claim 1 alone, US 7,977,488 is a compound claim, which typically provides broad enforcement against any product containing the same active identity, subject to the exact-salt interpretation.
Key Takeaways
- US 7,977,488 claim 1 protects one named small-molecule structure: 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine, plus “or a salt thereof.”
- Scope is structurally narrow but legally expandable via salts.
- Any broader landscape (dependent claims, formulation/method/process coverage, expiration dates, Orange Book listing, Paragraph IV challenges, and litigation) cannot be produced from the claim excerpt alone without the patent’s full record (claims set, specification-defined salt scope, priority and filing dates, assignee, and FDA listing ties).
FAQs
- Does US 7,977,488 cover different counterions beyond “pharmaceutically acceptable” salts?
- If a competitor markets a different salt polymorph of the same base, does claim 1 still read?
- Can a generic avoid infringement by using a different pyridinyl attachment position while keeping the rest of the scaffold constant?
- If a product uses the freebase instead of a salt, is it still within “or a salt thereof”?
- What litigation posture is typical when a compound claim like this is asserted in a Paragraph IV case?
References (APA)
- United States Patent No. 7,977,488. (Claim 1 text as provided in prompt).
More… ↓
⤷ Start Trial
|
